newsfilter
← Latest News
GlobeNewswire·

Monopar to Present at AASLD – The Liver Meeting® 2026: Phase 3 FoCus Baseline Data and ALXN1840 Molybdenum Safety Data

  • Monopar Therapeutics Inc. will present two abstracts on its investigational therapy ALXN1840 at the AASLD – The Liver Meeting 2026 in Denver, Colorado, from Nov. 5–9, 2026.
  • Dr. Frederick K. Askari will deliver an oral presentation on Sunday, Nov. 8, 2026, detailing baseline hepatic, neurologic, psychiatric disease burden findings from the Phase 3 FoCus trial.
  • Professor Aftab Ala will present a poster on Thursday, Nov. 5, 2026, regarding molybdenum balance lack of toxicity in patients treated with ALXN1840.
  • ALXN1840 is a first-in-class albumin tripartite complex activator that mobilizes excess copper demonstrated rapid sustained copper mobilization superior to standard of care in the Phase 3 pivotal trial.
  • Clinical data for ALXN1840 includes durable clinical improvement a favorable safety profile observed across 645 patient-years of follow-up in 266 patients.
  • Monopar Therapeutics also maintains radiopharmaceutical programs including MNPR-101-Zr for imaging MNPR-101-Lu MNPR-101-Ac for treating advanced cancers.
  • Presentation materials will be accessible in the Investors section of Monopar's website following the conference sessions.